Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 15/20 | 0.74 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938264 | 0.92 | SLC6A9 (0.76) | SLC6A9GPR55 | |
| SCHEMBL4943513 | 0.89 | SLC6A9 (0.68) | SLC6A9GPR55MEN1KMT2APTGS2 | |
| SCHEMBL4936410 | 0.89 | SLC6A9 (0.68) | SLC6A9GPR55MEN1KMT2APTGS2 | |
| SCHEMBL4940984 | 0.89 | SLC6A9 (0.68) | SLC6A9GPR55MEN1KMT2APTGS2 | |
| SCHEMBL4941678 | 0.89 | SLC6A9 (0.73) | SLC6A9GPR55MEN1KMT2APTGS2 | |
| SCHEMBL4942312 | 0.88 | SLC6A9 (0.67) | SLC6A9GPR55MEN1KMT2A | |
| SCHEMBL4943595 | 0.88 | SLC6A9 (0.71) | SLC6A9GPR55 | |
| SCHEMBL4940568 | 0.87 | SLC6A9 (0.70) | SLC6A9GPR55 | |
| SCHEMBL4948286 | 0.87 | SLC6A9 (0.79) | SLC6A9GPR55MEN1KMT2A | |
| SCHEMBL4943967 | 0.86 | SLC6A9 (0.69) | SLC6A9GPR55MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | SLC6A9 9/4885GPR55 485/4885MEN1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.